Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas
Rodrigo A. Toledo, Yuejuan Qin, Zi-Ming Cheng, et al.
Clinical Cancer Research (2015) Vol. 22, Iss. 9, pp. 2301-2310
Open Access | Times Cited: 123

Showing 1-25 of 123 citing articles:

Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma
Lauren Fishbein, Ignaty Leshchiner, Vonn Walter, et al.
Cancer Cell (2017) Vol. 31, Iss. 2, pp. 181-193
Open Access | Times Cited: 646
AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications
Chenjing Zhu, Yuquan Wei, Xiawei Wei
Molecular Cancer (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 393
Fibroblast growth factor receptors as treatment targets in clinical oncology
Masaru Katoh
Nature Reviews Clinical Oncology (2018) Vol. 16, Iss. 2, pp. 105-122
Closed Access | Times Cited: 301
Giving AXL the axe: targeting AXL in human malignancy
Carl M. Gay, Kavitha Balaji, Lauren A. Byers
British Journal of Cancer (2017) Vol. 116, Iss. 4, pp. 415-423
Open Access | Times Cited: 290
New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification
Joakim Crona, David Taïeb, Karel Pacák
Endocrine Reviews (2017) Vol. 38, Iss. 6, pp. 489-515
Open Access | Times Cited: 279
Personalized Management of Pheochromocytoma and Paraganglioma
Svenja Nölting, Nicole Bechmann, David Taïeb, et al.
Endocrine Reviews (2021) Vol. 43, Iss. 2, pp. 199-239
Open Access | Times Cited: 263
Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas
Rodrigo A. Toledo, Nelly Burnichon, Alberto Cascón, et al.
Nature Reviews Endocrinology (2016) Vol. 13, Iss. 4, pp. 233-247
Open Access | Times Cited: 244
Mitochondrial Complex II: At the Crossroads
Ayenachew Bezawork‐Geleta, Jakub Rohlena, Lan‐Feng Dong, et al.
Trends in Biochemical Sciences (2017) Vol. 42, Iss. 4, pp. 312-325
Open Access | Times Cited: 232
H3F3A (Histone 3.3) G34W Immunohistochemistry
Fernanda Amary, Fitim Berisha, Hongtao Ye, et al.
The American Journal of Surgical Pathology (2017) Vol. 41, Iss. 8, pp. 1059-1068
Open Access | Times Cited: 189
An overview of 20 years of genetic studies in pheochromocytoma and paraganglioma
Alexandre Buffet, Nelly Burnichon, Judith Favier, et al.
Best Practice & Research Clinical Endocrinology & Metabolism (2020) Vol. 34, Iss. 2, pp. 101416-101416
Open Access | Times Cited: 146
Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas
Rocio García‐Carbonero, F. Matute Teresa, Enrique Mercader-Cidoncha, et al.
Clinical & Translational Oncology (2021) Vol. 23, Iss. 10, pp. 1995-2019
Open Access | Times Cited: 117
Genotype–phenotype correlations in pheochromocytoma and paraganglioma: a systematic review and individual patient meta-analysis
Joakim Crona, Ángela Lamarca, Suman Ghosal, et al.
Endocrine Related Cancer (2019) Vol. 26, Iss. 5, pp. 539-550
Open Access | Times Cited: 112
Histone H3 Mutations: An Updated View of Their Role in Chromatin Deregulation and Cancer
Brandon R. Lowe, Lily Maxham, Joshua J. Hamey, et al.
Cancers (2019) Vol. 11, Iss. 5, pp. 660-660
Open Access | Times Cited: 111
Telomerase Activation and ATRX Mutations Are Independent Risk Factors for Metastatic Pheochromocytoma and Paraganglioma
Sylvie Job, Irena Drašković, Nelly Burnichon, et al.
Clinical Cancer Research (2018) Vol. 25, Iss. 2, pp. 760-770
Open Access | Times Cited: 105
Update of Pheochromocytoma Syndromes: Genetics, Biochemical Evaluation, and Imaging
Rami Alrezk, Andrés Suárez, Isabel Tena, et al.
Frontiers in Endocrinology (2018) Vol. 9
Open Access | Times Cited: 96
The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma
Lauren Fishbein, Jaydira Del Rivero, Tobias Else, et al.
Pancreas (2021) Vol. 50, Iss. 4, pp. 469-493
Closed Access | Times Cited: 93
Genomic Landscape of Pheochromocytoma and Paraganglioma
Ivana Jochmanová, Karel Pacák
Trends in cancer (2017) Vol. 4, Iss. 1, pp. 6-9
Open Access | Times Cited: 88
Gain-of-function mutations in DNMT3A in patients with paraganglioma
Laura Remacha, María Currás-Freixes, Raúl Torres, et al.
Genetics in Medicine (2018) Vol. 20, Iss. 12, pp. 1644-1651
Open Access | Times Cited: 85
New Insights on the Genetics of Pheochromocytoma and Paraganglioma and Its Clinical Implications
Sakshi Jhawar, Yasuhiro Arakawa, Suresh Kumar, et al.
Cancers (2022) Vol. 14, Iss. 3, pp. 594-594
Open Access | Times Cited: 59
Cabozantinib in patients with unresectable and progressive metastatic phaeochromocytoma or paraganglioma (the Natalie Trial): a single-arm, phase 2 trial
Camilo Jiménez, Mouhammed Amir Habra, Matthew T. Campbell, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 5, pp. 658-667
Closed Access | Times Cited: 11
Metabologenomics of Phaeochromocytoma and Paraganglioma: An Integrated Approach for Personalised Biochemical and Genetic Testing.
Graeme Eisenhofer, Barbara Klink, Susan Richter, et al.
PubMed (2017) Vol. 38, Iss. 2, pp. 69-100
Closed Access | Times Cited: 74
Targeted next-generation sequencing detects rare genetic events in pheochromocytoma and paraganglioma
Laurène Ben Aim, Pascal Pigny, Luis Jaime Castro‐Vega, et al.
Journal of Medical Genetics (2019) Vol. 56, Iss. 8, pp. 513-520
Open Access | Times Cited: 73
PheoSeq
María Currás-Freixes, Elena Piñeiro-Yáñez, Cristina Montero‐Conde, et al.
Journal of Molecular Diagnostics (2017) Vol. 19, Iss. 4, pp. 575-588
Open Access | Times Cited: 71
Oncogenic Mechanisms of Histone H3 Mutations
Daniel N. Weinberg, C. David Allis, Chao Lü
Cold Spring Harbor Perspectives in Medicine (2016) Vol. 7, Iss. 1, pp. a026443-a026443
Open Access | Times Cited: 65
Challenges in Paragangliomas and Pheochromocytomas: from Histology to Molecular Immunohistochemistry
C. Christofer Juhlin
Endocrine Pathology (2021) Vol. 32, Iss. 2, pp. 228-244
Open Access | Times Cited: 51
Page 1 - Next Page

Scroll to top